STEMPOINT CAPITAL LP

Stempoint Capital LP is a New York-based hedge fund specializing in the healthcare and life sciences sectors, filing quarterly 13F reports with the U.S. Securities and Exchange Commission under CIK #0001952142. The firm was founded by Peter Hartigan, who serves as Chief Investment Officer, bringing deep sector expertise and institutional investment experience to a platform designed to generate differentiated returns through specialized knowledge of healthcare markets. The firm's name — "Stempoint" — evokes the concept of a pivotal origin point, a metaphor that aligns with the firm's analytical mission of identifying inflection points in healthcare companies where scientific, clinical, or commercial developments are poised to unlock significant value. This naming convention reflects a broader investment philosophy centered on identifying catalytic moments in the life cycles of healthcare businesses. Structured as a limited partnership — the standard organizational form for hedge fund vehicles in the United States — Stempoint Capital operates within the established legal and regulatory framework for alternative investment management. The LP structure provides the firm with operational flexibility in managing investor capital while maintaining clear delineation between the general partner's management responsibilities and limited partners' investment interests. Headquartered in New York City, Stempoint Capital is situated at the center of the global healthcare investment ecosystem, with proximity to major pharmaceutical corporate headquarters, biotechnology clusters, leading research hospitals, sell-side healthcare analyst teams, and the investment banking franchises that finance the sector's capital-intensive development pipelines. This location provides the firm with direct access to the management teams, key opinion leaders, and scientific advisory networks that are essential to informed healthcare investment decision-making. The platform's 13F history tools allow users to trace every disclosed U.S. equity position across the firm's quarterly filing history, providing a complete record of its public market healthcare positioning.

Stempoint Capital LP employs a fundamentally driven long/short equity strategy with an exclusive focus on the healthcare and life sciences sectors. This sector-specialist approach represents a deliberate strategic choice to concentrate analytical resources and intellectual capital within a single complex domain where deep expertise creates durable informational and interpretive advantages over generalist investors. The healthcare sector is uniquely suited to specialist investment approaches due to its exceptional analytical complexity. Investment decisions in this space require the integration of scientific understanding (molecular biology, pharmacology, clinical trial design), regulatory expertise (FDA approval pathways, reimbursement frameworks, patent law), and commercial acumen (market sizing, competitive dynamics, physician adoption curves). Stempoint Capital's dedicated focus enables the team to develop the multi-disciplinary competence required to evaluate opportunities across the full spectrum of healthcare sub-sectors. The firm's investment process appears to span the entire healthcare value chain, from early-stage biotechnology companies with binary clinical catalysts through mature pharmaceutical and medical device businesses undergoing commercial or strategic transitions. The 13F Portfolio Composition across quarterly filings reveals a portfolio positioned across multiple healthcare sub-sectors, potentially including biopharmaceuticals, medical devices and diagnostics, healthcare services, managed care, life science tools, and specialty pharmaceuticals. This sub-sector diversification within the healthcare domain provides meaningful risk distribution while maintaining the analytical focus that is the firm's competitive advantage. On the long side, the strategy targets companies where the market underestimates the probability-weighted value of pipeline assets, the magnitude of commercial opportunities, or the strategic value embedded in differentiated platforms. Stempoint Capital likely employs sophisticated probability-adjusted valuation frameworks — a standard analytical approach among specialist healthcare funds — to assess the risk-adjusted value of clinical-stage assets where binary trial outcomes can generate significant price dislocations. On the short side, the firm seeks companies where consensus expectations are inflated relative to realistic clinical, regulatory, or commercial outcomes. Healthcare shorts can be particularly effective when grounded in deep scientific understanding, as the complexity of clinical data creates persistent informational asymmetries that generalist investors are slower to process. The Sector Allocation History within the healthcare domain illuminates the firm's sub-sector rotation patterns — whether it favors biotechnology over medical devices in certain market environments, or shifts between defensive healthcare names and higher-beta clinical-stage companies based on the prevailing risk appetite and catalyst calendar. This sub-sector positioning is a key differentiator among healthcare specialist funds and provides insight into the team's macro-aware overlay within its sector mandate. Turnover is estimated at moderate to high levels, reflecting the catalyst-driven nature of healthcare investing. Clinical trial readouts, FDA advisory committee meetings, regulatory decisions, and quarterly earnings reports create a continuous calendar of events around which positions are sized, initiated, or exited. The platform's backtesting service enables users to reconstruct the capital trajectory implied by these quarterly repositioning decisions and evaluate the compounding behavior of the disclosed long book over time.

Stempoint Capital LP represents an analytically rich profile as a New York-based healthcare sector specialist operating a long/short equity strategy within one of the most complex and informationally demanding domains in public equity markets. Filing under CIK #0001952142, the firm's quarterly 13F disclosures provide a detailed record of its U.S. healthcare equity positioning, enabling granular analysis of sub-sector preferences, position sizing methodology, and catalyst-driven portfolio management. Key analytical characteristics include: an exclusive healthcare sector focus that creates a concentrated but analytically deep investment approach; a catalyst-driven investment process that generates a distinctive return profile with binary event dependencies; and a long/short framework that provides partial hedging against systematic sector risk while maintaining the flexibility to express both positive and negative conviction across the healthcare landscape. The Annualized Return (CAGR) computed from the firm's disclosed long positions offers a measure of the healthcare long book's compounding behavior, capturing the cumulative impact of clinical catalysts, sector rotations, and stock-selection alpha. However, this metric reflects only the long side of the portfolio and does not incorporate short-side contributions, hedging costs, or the risk reduction benefits of the long/short structure. Distinctive analytical dimensions for ongoing study include: the firm's sub-sector allocation patterns (biotechnology versus pharmaceuticals versus medical devices versus services), which reveal strategic preferences and macro-sensitivity within the healthcare domain; the relationship between position sizing and proximity to binary catalysts, which illuminates the firm's risk management discipline; and the holding period distribution across different types of healthcare investments, which can differentiate between long-duration platform positions and shorter-term event-driven trades. A critical diagnostic question for ongoing monitoring: how does Stempoint Capital's concentrated healthcare portfolio navigate regime transitions in the biotech funding cycle — specifically, during periods when the IPO and secondary offering windows close, reducing capital availability for clinical-stage companies, does the firm's long/short flexibility enable it to profit from the resulting funding stress on the short side while repositioning its long book toward better-capitalized companies with near-term catalysts, or does the portfolio's overall beta to the healthcare innovation cycle create unavoidable drawdown exposure regardless of individual security selection?

The risk architecture of Stempoint Capital LP is shaped by its sector-concentrated mandate, the inherent binary risk characteristics of healthcare investing, and the long/short portfolio construction methodology that provides partial hedging against systematic sector drawdowns. Sector concentration risk is the defining feature of the firm's risk profile. By investing exclusively within healthcare and life sciences, Stempoint Capital accepts concentrated exposure to sector-specific risk factors — regulatory policy changes, drug pricing legislation, patent cliff dynamics, and shifts in the biotech funding environment — in exchange for the deeper analytical edge that specialization provides. During periods when healthcare underperforms the broader market, the fund's returns will reflect this sector beta regardless of the quality of individual security selection. Conversely, during healthcare leadership regimes, the fund captures the full benefit of sector tailwinds amplified by specialist stock-picking alpha. Binary and event risk is a structural characteristic of healthcare portfolios, particularly those with meaningful biotechnology exposure. Clinical trial results, FDA approval decisions, and key regulatory milestones can generate single-day price movements of 30% to 80% or more — in either direction — for individual holdings. The Max Drawdown Depth observable through historical replication of the firm's 13F filings captures the aggregate impact of these events on portfolio-level capital trajectory. Effective position sizing around binary events is a critical risk management skill for healthcare specialist managers, and the evolution of position sizes in the quarters leading up to and following major catalysts provides insight into the firm's risk calibration discipline. The Top 10 Holdings Concentration metric is particularly informative for evaluating the firm's balance between conviction and diversification within the healthcare space. A highly concentrated top-ten allocation amplifies both the upside from successful thesis execution and the downside from adverse clinical or regulatory outcomes. Monitoring this metric across filing periods reveals whether the firm maintains consistent concentration levels or dynamically adjusts its conviction weighting based on the catalyst calendar and prevailing sector risk conditions. Net exposure management through the long/short framework provides a mechanism for controlling directional sector risk. During periods of elevated sector uncertainty — such as election-year drug pricing rhetoric, pandemic-driven volatility, or FDA policy shifts — the firm can reduce net exposure by expanding its short book while maintaining gross exposure to continue generating stock-selection alpha. However, as with all long/short managers, the 13F filings capture only the long side and certain options positions, meaning the short book's contribution to risk management remains opaque in public disclosures. Liquidity risk varies significantly across the firm's portfolio depending on the market capitalization distribution of its holdings. Large-cap pharmaceutical and managed care positions typically offer deep liquidity, while small-cap and micro-cap biotechnology names may present significant liquidity constraints, particularly during periods of market stress or around binary events when trading volumes can be highly episodic. The Volatility Profile derived from filing-to-filing portfolio value changes provides a baseline measure of the firm's risk cadence, though quarterly observation intervals may smooth over the intra-quarter volatility that is characteristic of catalyst-driven healthcare portfolios.